Key Findings
A study published on ResearchGate demonstrates that aptamer-functionalized gold nanoparticles (AuNPs) exhibit remarkable efficacy in targeted drug delivery to gastric cancer cells. The research specifically highlights a significant enhancement in both targeting capability and anti-tumor effects when these nanoparticles are combined with laser irradiation, opening new avenues for improving the specificity and efficiency of cancer treatments.
Technical / Clinical Details
The study involved conjugating aptamers, which are single-stranded nucleic acids (DNA or RNA) capable of binding to specific target molecules with high affinity and selectivity (similar to antibodies), onto the surface of AuNPs. These aptamers were designed to recognize receptors overexpressed on gastric cancer cell surfaces, such as EGFR. Experiments confirmed that aptamer-functionalized AuNPs exhibited significantly improved targeting to gastric cancer cells compared to non-functionalized counterparts. Furthermore, after accumulation in cancer cells, external near-infrared laser irradiation triggered the photothermal effect of the AuNPs, generating heat that effectively accelerated cancer cell death. This combination of photothermal therapy and targeted drug delivery is part of a “theranostics” approach, aiming to maximize therapeutic effect while minimizing side effects. The study also explores controlling the valency (number of attached aptamers) and affinity (binding strength) of aptamer-conjugated nanoparticles to further enhance selectivity towards high-density EGFR-expressing cells, thereby effectively reducing off-tumor toxicity to healthy cells.
Background & Context
Gastric cancer is a leading cause of cancer-related morbidity and mortality worldwide, and treating advanced gastric cancer remains challenging. Conventional chemotherapies and radiation therapies often lack specificity, damaging healthy cells and causing severe side effects. Therefore, the development of targeted drug delivery systems that can precisely deliver therapeutic agents to cancer cells is an urgent need in gastric cancer treatment. Nanotechnology, with its small size and versatile functionalization capabilities, holds immense potential in this field. Aptamers are gaining recognition as superior alternatives to antibodies due to their stability, low immunogenicity, and ease of chemical synthesis, contributing to the development of “smart drug delivery systems” when combined with nanoparticles.
Strategic Significance & Outlook
Aptamer-functionalized gold nanoparticles hold transformative potential for improving the precision and safety of gastric cancer treatment. Future research will focus on rigorous evaluation of their in vivo efficacy and long-term safety profiles. Further developments are also expected in combination therapies with other anticancer agents and as theranostic devices integrating diagnostic imaging. This technology is also being considered for applications in other solid tumors (e.g., breast cancer, pancreatic cancer) and is expected to contribute significantly to the advancement of personalized medicine, ultimately improving patient prognosis and quality of life. The fusion of nanotechnology and molecular recognition promises to drive the next generation of cancer therapies.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments